Novavax: The Beaten-Down COVID-19 Darling (NASDAQ:NVAX)
· seekingalpha.com
Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million. Read why I rate NVAX stock a Buy now.
Novavax ( NVAX ) is a biotechnology company that was, during the COVID-19 time period, valued at over $19.5 billion; now it trades at just around $1.22 billion ...